Cipla has partnered with Stempeutics Research to launch Ciplostem, a therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine.
Through this launch, Cipla and Stempeutics reaffirm their collective focus on science- driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients’ everyday lives.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: